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The purinergic P2X7 receptor is expressed by bone cells and has been shown to be important in both bone formation and bone
resorption. In this study we investigated the importance of the genetic background of the mouse strains on which the P2X7 knock-
out models were based by comparing bone status of a new BALB/cJ P2X7−/− strain with a previous one based on the C57BL/6
strain. Female four-month-old mice from both strains were DXA scanned on a PIXImus densitometer; femurs were collected for
bone strength measurements and serum for bone marker analysis. Bone-related parameters that were altered only slightly in the B6
P2X7−/− became significantly altered in the BALB/cJ P2X7−/− when compared to their wild type littermates. The BALB/cJ P2X7−/−
showed reduced levels of serum C-telopeptide fragment (s-CTX), higher bone mineral density, and increased bone strength com-
pared to the wild type littermates. In conclusion, we have shown that the genetic background of P2X7−/− mice strongly influences
the bone phenotype of the P2X7−/− mice and that P2X7 has a more significant regulatory role in bone remodeling than found in
previous studies.
1. Introduction
In bone, endogenous nucleotides, such as ATP and UTP, are
released from many types of cells, including bone cells [1,
2]. Nucleotides are released in response to a number of
stimuli including inflammation [3, 4] and mechanical stim-
ulation [5–7]. They act as autocrine and paracrine signaling
molecules by activating purinergic (P2) receptors [8]. Bone
cells express several types of P2 receptors [9], allowing them
to respond diﬀerently to nucleotides, depending on the types
of nucleotide present, their concentration, and the duration
of exposure [8, 9]. The P2X7 receptor subtype is probably
one of the most important P2 receptors in the regulation of
bone turnover. It is most abundant in cells of haematopoetic
origin [10], including osteoclasts [8, 11], but also in osteo-
blasts that are of mesenchymal origin [12–14].
Several roles of P2X7 have been suggested including ATP-
induced apoptosis [12, 15, 16], maturation of interleukin-1β,
and its subsequent release [17]. Low agonist concentrations
lead to low-level activation of P2X7 receptors and might
initiate osteoclast formation through activation of path-
ways initiating production of transcription factors [18, 19].
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Prolonged exposure to high agonist concentrations induces
the formation of large pores in the membrane, permeable
to hydrophilic molecules as large as 900Da [20, 21]. P2X7
receptors are expressed in both osteoclast precursors and
active osteoclasts [8, 11, 22]. Therefore, in addition to acti-
vating the apoptotic pathway, the P2X7 receptor could play a
role in osteoclast development [23, 24] and activation [25].
To further explore the role of the P2X7 receptor in the
regulation of the skeletal system, the bone phenotype of
two mouse models with ablation of the P2X7 receptor was
examined [13, 22, 26]. Both of these exhibited a skeletal
phenotype diﬀerent from the genetic background strain.
The P2X7 knock-out model first published by Solle et al.
[27] showed reduced total bone mineral content (BMC),
decreased periosteal bone formation, and increased bone
resorption [13], which resembles the eﬀects of disuse on
the skeleton. In line with this it was shown that P2X7−/−
mice have impaired response to mechanical loading [26].
The eﬀects are partially due to increased osteoclast numbers
which were further supported by in vitro studies showing
that the P2X7 receptor is not necessary for murine osteoclast
formation [13]. The second murine P2X7 knock-out model
generated by Chessell et al. [28] shows a diﬀerent bone phe-
notype with increased cortical thickness of the tibial shaft,
but surprisingly no changes in total BMD [22].
The contradicting observations have been attributed to
the dissimilar sample sizes, methods of the gene knockout,
and diﬀerent genetic backgrounds of the inbred strains used
to generate the mice. Solle’s P2X7−/− mice were generated
on 129/Ola, C57Bl/6 (B6), and DBA/2 mixed genetic back-
ground but afterwards maintained on the B6xDBA/2 back-
ground [13, 27], hereafter called DBAxB6 P2X7−/−. The
P2X7−/− mice generated by Chessell et al. were maintained
on B6 background but originate from a B6/129 hybrid [28],
hereafter called B6 P2X7−/−.
Interestingly, mice of the DBA and B6 background have a
naturally occurring mutation in the P2X7 receptor as shown
by Adriouch et al. [29]. Presence of the mutation impairs the
normal function of the receptor; HEK cells transfected with
constructs of both genotypes showed that ATP-induced pore
formation was reduced by 50% in cells carrying the mutated
allele (451L) [29]. In osteoclasts from mouse strains carrying
the 451L allele we found a reduction in pore-forming activity
compared to osteoclasts from strains carrying the P451 allele
[30]. In murine thymocytes the P451L mutation aﬀects the
mechanism of apoptosis acting through the pore formation
induced by ATP [31]. As the response of the P2X7 receptor to
ATP is lower in cells harbouring the 451L allele of the P2X7
gene, consequently the observed eﬀects of the P2X7−/− in the
two models may have been underestimated in the published
studies. By introducing a diﬀerent genetic background to a
P2X7−/− model a more pronounced bone phenotype could
maybe be found.
In support of this, we recently showed that DBA/2 and
B6 mice have low BMD along with impaired bone strength
[30], which could make it diﬃcult to detect ovariectomy-
induced bone loss in mouse models of postmenopausal
osteoporosis. Therefore, both the B6 and DBA are less suit-
able as mouse models of osteoporosis. Of the four inbred
strains of mice that have been reported to have the P451
allelic genotype [29], only 129X1/SvJ and BALB/cJ proved
ideal for a new P2X7−/− strain. Both strains had high base-
line BMD, relatively strong bones and high trabecular bone
volume [30]. Since the 129X1/SvJ strain is resistant to can-
cellous bone loss induced by ovariectomy [32] only the
BALB/cJ strain is suitable as a candidate strain for the gen-
eration of a new P2X7 knock-out model. The BALB/cJ mice
are characterized by having high BMD, high Tb.Th, and
trabecular numbers along with strong bones. Since the
BALB/cJ mice clearly respond to ovariectomy with bone loss
[33], it is well suited for studying the bone specific eﬀect of
P2X7 knock-out.
Therefore, the overall aim of this study was to generate a
new P2X7−/− strain with a genetic background not harbour-
ing the P451L mutation subsequent to characterizing the
BALB/cJ P2X7−/− mice and comparing the bone phenotypes
of this model with that of the B6 P2X7−/−.
2. Materials and Methods
2.1. Animals. Female mice of the B6 P2X7−/− strain [28]
were kindly provided by GlaxoSmithKline and crossed into
the BALB/cJ inbred strain from Jackson Laboratories (Bar
Harbor, ME) for five generations. Founders were selected by
PCR for the knockout of exon of the P2X7 gene. Since the
mice generated were only insipient congenic with the BALB/
cJ genome (∼97%), wild type littermates from heterozygote
breeding couples were used as control groups in both strains,
instead of inbred B6 or BALB/cJ.
Requests for BALB/cJ P2X7 animals should be addressed
to Niklas Rye Jørgensen (Niklas@dadlnet.dk). The authors
do not currently have access to B6 P2X7−/− animals, so
requests for these should be directed to GlaxoSmithKline.
2.2. Study Protocol. All animal procedures were approved by
The Danish Animal Welfare Council prior to initiating the
experiments (protocol: 2002/561–634 and 2006/561–1209).
Female mice (n = 15 mice per strain) were kept at a 12 : 12
hour light/dark cycle at 20±0.7◦C, fed the Purina mouse diet
formula 5K52 (Purina, St. Louis, MO), and had access to tap
water ad libitum. Ten and two days before sacrifice, animals
were injected with 25mg/kg tetracycline i.p. or 20mg/kg
calcein i.p., respectively, in order to label formative surfaces
of bone for dynamic bone histomorphometry. At the age of
120 days, they were starved overnight (tominimize biological
variation in bone markers) and euthanized by CO2. Blood
was collected into 2mL syringes by cardiac puncture, and
serumwas collected for later measurements of bone markers.
The animals were scanned on the PIXImus (Lunar Corp.)
densitometer shortly after blood was collected.
2.3. P2X7−/− Genotyping. P2X7−/− animals of both strains
(B6 and the BALBc/J) were genotyped by PCR using the
protocol outlined in the following. Earpieces or tail parts
were used for DNA isolation with the QIAamp DNA Blood
Mini Kit (Qiagen), which was used as template in PCR
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reactions. The primers used were Forward primer (P2X7-
GT1): 5′ GGG GTG GTG AAG AAA TGA A 3′, Reverse
primer (P2X7-GT2): 5′ GGA TGT GCT GCA AGG CGA
TT 3′, Reverse primer (P2X7-GT3): 5′ CCA CTT GAC
GGT GCC ATA 3′. The P2X7-GT1 and P2X7-GT2 primers
amplify a 2473 bp product for the P2X7−/− mouse, while the
P2X7-GT1 and P2X7-GT3 primers amplify a 2447 bp prod-
uct for the wild type mouse. Because of the similarity of the
two bands the two primer pairs were used in two diﬀerent
PCR reactions. The samples were amplified using a PCR
cycler (MJ Research Inc.) with the following program. After
preheating at 95◦C for 15min, 35 cycles were run, with dena-
turation at 94◦C, annealing at 56◦C for 1min, extension at
72◦C for 1min before final extension for 10min at 72◦C.
PCR products were loaded on a 1% agarose gel (IBI agarose,
Shelton Scientific Inc.) for electrophoresis. The amplicons
were visualized under UV light using the GeneGenius gel
imaging system from Syngene.
2.4. Bone Formation and Resorption Markers. To investigate
possible diﬀerences in bone formation markers between the
genotypes, osteocalcin was measured in serum samples in
duplicate using the Mouse Osteocalcin RIA Reagents from
Biomedical Technologies, Inc. (Stoughton, MA), following
the protocol supplied with the reagents. Interassay CV was
12% and intraassay CV was 6%.
Bone resorption as expressed by fragments of type I col-
lagen (CTX) in mouse serum was measured in duplicate
using the RatLaps Elisa Assay (C-telopeptide collagen type I
fragment Assay) developed by Nordic Bioscience Diagnostics
(Herlev, Denmark) and following the procedure supplied
with the kit. Interassay CV was 14.8% and intraassay CV was
9.2%.
Alkaline phosphatase activity was measured in duplicate
in mouse serum using the Alkaline phosphatase Reagent Kit
(Sigma). The kit measures total alkaline phosphatase activity
and does not distinguish the diﬀerent organ-specific sub-
types. Alkaline Phosphatase activity was measured directly
on the serum in the multiwell plates, using a slight modifi-
cation of the standard clinical chemistry procedure. Serum
replicas were diluted with alkaline buﬀer solution, and sub-
strate solution was added to each well, and the plate was
incubated at 37◦C for 30min. Finally 2.0MNaOHwas added
to each well to stop the reaction. Absorbance was measured
on a plate reader at 405 nm. Interassay CV was 5.9% and
intra-assay CV was 2.4%.
2.5. Bone Strength Measurements. On the day of sacrifice
the mouse femurs were collected, cleaned for soft tissue,
wrapped in saline moistened gauze in a tube, and frozen at
−20◦C for later ex vivo biomechanical measurements, as
described earlier [34]. The strength of the femoral diaphysis
was determined by a 3-point bending test on a Lloyd Instru-
ments compression device (LR50K, Lloyd Instruments, Fare-
ham, UK), after rehydration in a saline solution at room
temperature. Load-deformation curves were generated, and
maximal load was recorded at a speed of 2mm per minute
with a 100N load cell.
2.6. Bone Histomorphometry. To investigate histologic and
morphometric changes in the P2X7−/− models histomor-
phometric analyses were performed. In short the total spines
and tibias were collected and fixed in 70% ethanol at 5◦C.
After methyl-methacrylate embedding, bones were sectioned
into 7 μm thick slices on a Polycut E (heavy-duty microtome)
and mounted on slides. Five subsequent slides were stained
with Goldner-Trichrome for determination of bone volume
in percentage of total volume (BV/TV, %), cortical thickness
(C.Th, μm), trabecular thickness (Tb.Th, μm), and eroded
surface as percentage of bone surface (ES/BS). Five slides
from each bone were left unstained for quantification of
mineralizing surfaces as percentage of bone surface (MS/BS,
%) under fluorescent light. Further, mineral appositional
rate (MAR, μm/day) was calculated. The previously men-
tioned indices were determined using an Olympus BX51
microscope equipped with a C.A.S.T.-Grid system and
reported according to standard bone histomorphometry
nomenclature.
2.7. Statistics. Statistical analyses were performed using the
SPSS software, v.11.5. Standard parametric tests were used.
Diﬀerences were considered statistically significant when P ≤
0.05. Simple descriptives were presented asmeans± standard
error of the mean (SEM). The two types of knockout ani-
mals were compared to the respective wild type animals by
Student’s t-test.
3. Results
3.1. Comparison of the Two P2X7+/+ Strains.The new P2X7−/−
strain was made by backcrossing the B6 P2X7−/− mice gene-
rated by Chessell et al. [28] into the BALB/cJ inbred strain
for five generations, hereafter called BALB/cJ P2X7−/−. As
a point of reference there were no significant diﬀerences
between the wild type (P2X7+/+) mice of the two strains
used for the knockout in the majority of assessed bone
parameters (Table 1), but the BMD, femoral strength, and
concentration of bone markers were significantly lower in
the B6 strain (Table 1, Figures 1(b) and 1(c)) than in the
BALB/cJ. Furthermore, bone resorption (levels of s-CTX and
ES/BS%) were lower in the wild type B6 compared to the
wild type BALB/cJ strain (Tables 1 and 2 and Figure 1(d)),
and the bone formation markers alkaline phosphatase and
osteocalcin were decreased in the B6 (Table 1).
3.2. B6 P2X7−/− Mice. There were no significant diﬀerences
in the basic characteristics such as weight, length, and body
composition between the two genotypes of the B6 P2X7
animals (data not shown). The markers of bone resorption
and bone formation did not alter significantly when P2X7
was ablated in the B6 mice (Table 2). The increase in whole
body BMD (4.5%, P = 0.011) in B6 P2X7−/− compared to
the P2X7+/+ animals (Figure 1(a)) was accompanied by sig-
nificant increased bone strength in B6 P2X7−/−, 18.22N
compared to 16.29N in B6 P2X7+/+ (P = 0.018). The
histomorphometric analysis of bone indices in the vertebrae
showed only significant increase in Tb.Th in B6 P2X7−/−
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Figure 1: Bone mineral density, bone strength, and serum concentration of the resorption marker in the P2X7−/− in the strains BALB/cJ
and B6 compared to their wild type littermates, displayed as means ± SEM. (a) Bone mineral density in BALB/cJ and B6 measured by DXA
scanning on the PIXImus. The mice homozygote for the P2X7 deletion in both strains had significant higher BMD than the wild type. There
was also significant diﬀerence in BMD between the two wild type groups. (b) Bone mineral density in the femoral region of BALB/cJ and
B6 measured by DXA scanning on the PIXImus. The mice homozygote for the P2X7 deletion in both strains had higher BMD than the
wild type; however it was only significant in the BALB/cJ strain. There were also significant diﬀerences in BMD between the two wild type
groups. (c) Strength of femurs in BALB/cJ and B6 measured by a three-point bending test. The mice homozygous for the P2X7 deletion in
BALB/cJ had significant stronger bones than the wild type BALB/cJ. B6 wild type bones were significantly weaker in the test and only a
small significant diﬀerence when compared to the knockout group. (d) Concentration of s-CTX (ng/mL) in BALB/cJ and B6. There were no
significant diﬀerences between the wild type and homozygote in the B6 strains. In BALB/cJ the serum concentration was significantly 46%
lower in the KO animals compared to the wild type.
mice (P = 0.011) compared to B6 P2X7+/+ (Table 2). Histo-
morphometric analysis of the proximal tibia revealed that
in resemblance with the vertebrae Tb.Th was increased
(32.3 μm to 35.5 μm) however not significant in this region
(P = 0.119). As seen on Figure 2, the thickness of the
tibial cortex was increased to 162.6 μm in B6 P2X7−/− com-
pared to 127.4 μm in B6 P2X7+/+ (P < 0.001). When the
histomorphometric indices of B6 P2X7−/− were compared
to B6 P2X7+/+, the changes were of diﬀerent amplitude and
direction in the two regions, tibia and vertebrae, as presented
in Table 2.
3.3. BALB/cJ P2X7−/− Mice. First, we analyzed the data con-
cerning the basic characteristics such as weight, length, and
body composition (lean versus fat tissue). No significant dif-
ference between BALB/cJ P2X7−/− mice and wild type litter-
mates was found (Table 1). The total BMD in BALB/cJ
P2X7−/− assessed by DXA, was higher compared to wild type
animals (Figure 1(a), Table 1); however here the diﬀerence
between genotypes was higher in the BALB/cJ strain than in
the B6 strain. Also diﬀerences in BMC were detected, with
the higher value in the knock-outs (0.470 g versus 0.558 g,
P < 0.001), as well as in bone area, again assessed by DXA
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Table 1: Basic characteristics from DXA scanning, three-point-bending test, and bone marker analysis.
N Mean SEM N Mean SEM P
B6 B6+/+ B6−/− t-Test
Body weight (g) 15 20.12 0.45 14 21.65 1.63 0.380
Lean tissue (g) 15 15.6 0.3 14 15.7 0.4 0.786
Fat tissue (g) 15 4.2 0.3 14 5.5 1.5 0.427
Fat percentage 15 20.8 1.3 14 22.7 3.1 0.587
Bone area (cm2) 15 9.10 0.10 14 9.07 0.14 0.847
Whole body BMC (g) 15 0.454 0.007 14 0.473 0.012 0.179
Whole body BMD (g/cm2) 15 0.0499 0.000 14 0.0521 0.0006 0.005
Femur length (mm) 15 15.50 0.05 13 15.66 0.21 0.500
Femoral BMC (g) 15 0.036 0.001 14 0.037 0.001 0.321
Femoral BMD (g/cm2) 15 0.0650 0.0007 14 0.0682 0.0012 0.038
Maximal load (N) 15 16.29 0.29 14 18.22 0.68 0.018
RatLabs (ng/mL) 15 9.7 0.5 14 9.1 0.6 0.441
ALP concentration (nmol/mL) 12 247.6 13.5 13 241.0 12.7 0.727
Osteocalcin (ng/mL) 15 39.2 2.9 14 44.5 2.4 0.161
BALB/cJ BALB/cJ+/+ BALB/cJ−/− t-Test
Body weight (g) 14 20.68 0.28 15 20.42 0.25 0.499
Lean tissue (g) 14 16.3 0.2 15 16.1 0.2 0.555
Fat tissue (g) 14 3.6 0.1 15 3.3 0.1 0.069
Fat percentage 14 18.0 0.4 15 17.0 0.4 0.086
Bone area (cm2) 14 9.19 0.08 15 9.90 0.13 <0.001
Whole body BMC (g) 14 0.471 0.008 15 0.558 0.009 <0.001
Whole body BMD (g/cm2) 14 0.0513 0.0005 15 0.0563 0.0005 <0.001
Femur length (mm) 14 15.06 0.17 15 15.61 0.16 0.029
Femoral BMC (g) 14 0.040 0.001 15 0.044 0.001 0.004
Femoral BMD (g/cm2) 14 0.0764 0.0006 15 0.0826 0.0010 <0.001
Maximal load (N) 14 24.62 0.44 15 33.95 0.59 <0.001
RatLabs (ng/mL) 14 19.1 1.2 15 8.8 0.5 <0.001
ALP concentration (nmol/mL) 14 314.2 11.0 14 270.6 15.0 0.028
Osteocalcin (ng/mL) 14 55.9 3.1 15 63.2 2.9 0.101
analysis, from 9.19 cm2 to 9.90 cm2 (P < 0.001). Bone min-
eral density of the femur was increased by 8.2% (P < 0.001,
Figure 1(b)), and bone strength was improved as much as
37.9% in BALB/cJ P2X7−/− animals (P < 0.001, Figure 1(c))
when compared to wild type animals. BALB/cJ P2X7−/− mice
have low levels of s-CTX, as seen in Figure 1(d) and Table 1;
interestingly, it is markedly reduced in BALB/cJ mice (8.76 ng
telopeptide/mL serum) compared to wild type animals
(19.09 ng telopeptide/mL serum) (P < 0.001). The non-
bone-specific alkaline phosphatase decreased significantly
from 314.2 nmol/mL to 270.6 nmol/mL in BALB/cJ P2X7−/−
mice (P = 0.028). There were no significant changes in con-
centration of the formation markers osteocalcin (P = 0.101,
Table 1). No significant diﬀerences for the BALB/cJ strain in
any of the bone histomorphometric indices analyzed were
detected (Table 1).
4. Discussion
The role of P2X7 in the regulation of bone turnover has
already been established over the last decade. Extracellular
nucleotides have been shown to be involved in calcium sig-
nalling and thus intercellular communication among osteo-
blasts [8]. Nevertheless, the reported eﬀects of the relatively
specific P2X7 agonist BzATP on the activity of bone cells in
vitro have been conflicting [12, 18, 19].
In the current study, we have shown that the P2X7 recep-
tor has a distinct role in the regulation of bone mass and
turnover, as BMD was increased in P2X7−/− mice from two
strains with diﬀerent genetic backgrounds. The mechanisms
underlying the rise in BMD are presumably multiple but
could be related to the observed changes in bone formation
and resorption markers, even though no diﬀerence was seen
in the histomorphometric analyses.
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Table 2: Histomorphometric analysis for B6 and BALB P2X7+/+ and P2X7−/− mice.
B6 B6+/+ B6−/− t-Test
Vertebrae Mean SEM Mean SEM P
N 12 8
MS/BS% 43.8 2.9 42.5 3.9 0.796
MAR (μm/day) 1.07 0.03 1.00 0.04 0.077
ES/BS (%) 7.9 0.4 9.1 0.7 0.180
BV/TV (%) 17.7 1.5 20.4 0.9 0.122
Tb.Th. (μm) 32.8 1.1 36.5 0.7 0.011
C.Th. (μm) 93.0 3.6 93.7 4.8 0.917
Tibia Mean SEM Mean SEM P
N 12 8
MS/BS% 46.1 2.1 44 2.4 0.517
MAR (μm/day) 1.16 0.03 1.2 0.04 0.378
ES/BS (%) 8.3 0.6 8.0 0.3 0.676
BV/TV (%) 10.0 1.7 13.2 1.7 0.197
Tb.Th. (μm) 32.3 1.1 35.5 1.7 0.138
C.Th. (μm) 127.4 3.8 162.6 6.1 <0.001
BALB/cJ BALB/cJ+/+ BALB/cJ−/− t-Test
Tibia Mean SEM Mean SEM t-Test
N 7 7
MS/BS% 44.8 5.7 53.4 4.1 0.267
MAR (μm/day) 1.00 0.03 ND —
ES/BS (%) 10.15 0.5 9.9 0.9 0.791
BV/TV (%) 8.7 1.7 9.5 1.9 0.766
Tb.Th. (μm) 31.1 2.1 33.1 1.1 0.423
C.Th. (μm) 148.9 10.4 139.8 8.9 0.517
Changes in histomorphometric parameters in P2X7−/− compared to P2X7+/+ in the tibia and vertebral (only B6). Displayed as mean ± SE for the group. The
direction of changes is equal in the diﬀerent regions of the B6 mice, besides MAR where it is decreased in the vertebral region of P2X7−/− and decreased in
the tibia. The ES/BS (%) has the opposite directions in vertebrae and tibia. Besides the cortical thickness and MS/BS (%) the directions of changes are the
opposite in the BALB mice compared to the B6 mice. The size of the changes in the histomorphometric parameters P2X7−/− mice is diﬀerent in relation to
region and strain analyzed. Significant diﬀerences from wild type animals at the P < 0.05 levels, determined by Student t-test, are displayed.
(a) (b)
Figure 2: Representative photomicrographs of Goldner-Trichrome stained slices of proximal tibia from (a) P2X7−/− and (b) wild type
animals of B6 strain.
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The new P2X7−/− on BALB/cJ background (BALB
P2X7−/−) showed significantly increased BMD, BMC, and
bone area determined by DXA compared to the wild type
genotype. BMD/BMC was also increased in the femoral
region, which was accompanied by an increase in bone
strength of the femoral diaphysis. The diﬀerence could be
caused by reduced resorption compared to bone formation,
since we found big reduction in s-CTX and a significant
decrease in the bone formation marker alkaline phosphatase.
Morphological changes in other compartments could also
explain the observed results, but these have not been inves-
tigated in this study. Almost the same picture was present
when the B6 P2X7−/− mice were examined though the eﬀect
sizes were smaller. Thus, the increases in BMDs and in
femoral strength were smaller. When histomorphometric
analysis of the vertebrae was compared to the tibia, site-
specific diﬀerences were detected in the resorption index
ES/BS%, but even the eﬀect was in the opposite direction;
it was insignificant at both sites. The measured Tb.Th was
significantly higher in the vertebrae but not in the tibia. We
found increased C.Th in the proximal tibia, but not in the
vertebrae. The fact that we observe the same eﬀect of P2X7
ablation, but with a smaller eﬀect size in the strain carrying
the 451L allele, confirms the role of the P2X7 receptor in
regulation of bone mass.
Serum CTX levels express the total bone resorbing
activity of the organism, and interestingly we found striking
diﬀerences in s-CTX between the two strains. In BALB/cJ, the
wild type animals have a significantly higher s-CTX level
than both the corresponding knock-out and the B6 wild
type (Figure 1(d)). In contrast, the B6 wild type and the
B6 P2X7−/− s-CTX levels are not diﬀerent, suggesting a
distinct role of the cytoplasmic tail of the P2X7 receptor in
osteoclastic bone resorption. In a former study we found
a reduction in pore formation in osteoclasts from the B6
strains compared to osteoclasts from the BALB/cJ, but no
diﬀerence in resorptive activity of cultures not stimulated
with nucleotides [30]. Even though there are multiple genetic
diﬀerences between the two strains, the major finding in
this study is that the genetic background is of significant
importance when determining the eﬀect of the P2X7 abla-
tion.
As seen in Figure 2, our study confirms the results of the
previous study where Gartland et al. showed increased cor-
tical thickness in tibia of P2X7−/− [22]. Since they were not
able to detect any diﬀerence in the formation and number
of osteoclasts, they suggested that the apoptosis of the osteo-
blasts was aﬀected. They also observed an increased number
of osteocytes in cortex, suggesting that instead of undergoing
apoptosis the osteoblasts were incorporated in matrix. That
could be a plausible explanation for the diﬀerences found
in B6 P2X7−/−, but it cannot explain the decrease in s-CTX
in the BALB P2X7−/−. In the study by Ke et al., they found
an increased number of osteoclasts in Pfizers DBA/B6
P2X7−/− tibiae but could not detect any diﬀerence in osteo-
clastogenesis in vitro [13]. Gartland et al. also reported that
there was no significant diﬀerence in the development of
osteoclasts between B6 P2X7−/− and B6 WT in vitro [22].
The question is if the unnatural culture conditions, for
example, the lack of systemic hormones, accessory cells, and
mechanical stimulation, could explain the lack of eﬀect of
P2X7 ablation upon osteoclasts when assessed in vitro com-
pared to the diﬀerences seen in vivo/ex vivo.
Finally, the recently described P2X7-k splice variant
suggested to escape knockout in the Glaxo mice [35] could
be a contributing factor to the diﬀerences between the Glaxo
and Pfizer models. However, even though normal osteoclasts
express P2X7, none could be detected in osteoclasts derived
from BALB/cJ-P2X7−/− mice, indicating that the P2X7-k
expression splice variant was undetectable on the protein
level [36].
However, even if there are some conflicting results from
the two diﬀerent models of P2X7 knock-out in mice, they
both point towards an important role of the receptor in reg-
ulation of bone formation. It emphasizes that even though
mice are widely used as models to study the regulation of
bone mass and turnover, there are important diﬀerences bet-
ween murine and human bone physiology. Human studies
are highly warranted to investigate the role of the P2X7 recep-
tor in human bone turnover and in conditions of altered
bone metabolism.
The two background strains on which the B6xDBA
P2X7−/− from Pfizer and B6 P2X7−/− from Glaxo mice were
based carry the 451L allele of the naturally occurring muta-
tion in P2X7. The contradictory eﬀects on bone status bet-
ween the two strains could be due to a number of factors,
including diﬀerences in experimental parameters like sex,
age, or diet [13, 22], which makes it diﬃcult to compare the
experiments with diﬀerent background. Ke et al. found a
larger eﬀect of the knockout in DBA/B6 P2X7−/− males com-
pared to the females. Gartland et al. do not inform about
the sex of the B6 P2X7 animals in their study [22]. In our
study, only females were used. Of critical importance is the
choice of wild type animals, whether it is wild type siblings
from heterozygote breeding couples or purchased from the
inbred background strain. Another important parameter to
consider is the diet, as it is known to influence bone mass and
structure. Our earlier experiments with the B6 P2X7 mice
showed only insignificant diﬀerences in s-CTX. By changing
the diet from Altromin 1430 or 1319 to LabDiet 5K52, which
contains more calcium (0.8% to 1.15%), more D-vitamin
(1 IU to 4 IU), and less fat (7.5% to 4%) it showed significant
eﬀects on the BMD, also in female mice. In this study the
BALB and B6 P2X7−/− mice were fed the same diet and
had similar age and sex, so the only diﬀerence is the genetic
background. Bouxsein et al. have shown that the genetic
background is extremely important for the bone status in the
diﬀerent strains [33]. In this study BALB/cJ mice had higher
bone turnover (indicated by levels of s-CTX and alkaline
phosphatase) than B6. Therefore it is possible that it is easier
to detect the decrease in resorption in the P2X7−/− on the
BALB/cJ background. Similar strain-specific diﬀerences are
seen in other knockout mice, like diverse eﬀects of treatment
are seen in diﬀerent strains [37].
In conclusion, we have shown that the P2X7 receptor
plays an important role in the control of bone remodelling.
Furthermore, absence of P2X7 receptor expression seems to
be associated with increased bone mass and strength in two
8 Journal of Osteoporosis
mouse models. The eﬀect of P2X7 ablation was underestima-
ted in the model based on the B6 strain carrying the naturally
occurring mutation, since the diﬀerence between the knock-
outs and their wild type littermates is higher in the BALB/c
model than in the B6 model. Further studies are warranted
in order to understand the complex roles of P2X7 in bone
turnover, where especially human studies are important in
order to fully understand the role of the receptor in human
bone physiology.
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